Veracyte to Unveil Practice-Altering Genomic Diagnostics Data Across Several Oncology Indications at 2021 ASCO

Tom Smith

– Pivotal clinical validation data for Percepta Nasal Swab exam in early lung cancer detection – – New knowledge demonstrating ability of Decipher Prostate take a look at to recognize higher metastasis risk in African American gentlemen – Veracyte, Inc. (Nasdaq: VCYT), a international genomic diagnostics enterprise with a presence […]

– Pivotal clinical validation data for Percepta Nasal Swab exam in early lung cancer detection –

– New knowledge demonstrating ability of Decipher Prostate take a look at to recognize higher metastasis risk in African American gentlemen –

Veracyte, Inc. (Nasdaq: VCYT), a international genomic diagnostics enterprise with a presence in seven of the top rated ten cancers in the United States, announced now that six abstracts for its genomic exams in lung, prostate and thyroid cancers will be introduced at the 2021 ASCO Annual Conference, which will be held practically June 4-8, 2021.

The approved abstracts include pivotal medical validation knowledge for Veracyte’s Percepta Nasal Swab. This to start with-of-its-variety, non-invasive exam will assistance doctors establish which sufferers with lung nodules located on CT scans are at very low possibility for cancer and can be safely and securely directed to plan monitoring without panic of lacking a cancer and which individuals should really go through further more, such as most likely far more-intense, clinical perform-up. Veracyte programs to introduce the nasal swab-based mostly genomic examination in the 2nd half of 2021, as part of the company’s extensive lung cancer portfolio.

“We are thrilled with the powerful facts that will be introduced at ASCO, which mirror our tests’ potential to positively effects individual treatment in a array of big cancers,” claimed Bonnie Anderson, Veracyte’s chairman and main govt officer. “We are specially fired up about the opportunity in lung cancer, exactly where early detection can conserve life, but wherever distinguishing concerning cancerous and benign lung nodules is usually challenging and can guide to skipped cancers or pointless processes. We think our Percepta Nasal Swab take a look at is going to be a game-changer for individuals staying evaluated for lung most cancers.”

Between other Veracyte highlights, researchers will share future validation knowledge for the Decipher Prostate test, demonstrating the genomic test’s potential to predict aggressive prostate cancers between African American gentlemen as as opposed to the use of scientific variables by itself.

Beneath are facts of the Veracyte abstracts recognized for presentation at ASCO. All posters will be out there to meeting registrants on need starting June 4, 2021, at 9:00 a.m. EDT.

Title:

Early prospect nasal swab classifiers formulated working with device mastering and complete transcriptome sequencing may possibly improve early lung cancer detection.

(Title of poster to be presented: A validated nasal swab classifier developed working with device learning and entire transcriptome sequencing may well enhance early lung most cancers detection.)

Summary #:

8551

To start with Author:

Peter Mazzone, M.D., M.P.H., Cleveland Clinic

Title:

A possible Validation of the genomic classifier defines large-metastasis possibility in a subset of African American gentlemen with early localized prostate cancer: VanDAAM examine. (oral presentation)

Abstract #:

5005

Initial Creator:

Kosj Yamoah, M.D., Ph.D., Moffitt Cancer Centre

Time:

June 8, 2021, 8:00-11:00 a.m. EDT

Title:

The effect of Percepta Genomic Sequencing Classifier (GSC) on clinical conclusion making in patients with a high- possibility lung nodule. (poster presentation)

Abstract #:

8549

Initially Writer:

Sonali Sethi, M.D., Cleveland Clinic

Title:

Validation of the Decipher Genomic Classifier (GC) in SAKK 09/10: A Section III Randomized Trial of Dose-Escalated Salvage Radiotherapy (SRT) immediately after Radical Prostatectomy (RP). (poster presentation)

Summary #:

5010

Initial Author:

Alan Dal Pra, M.D., University of Miami Overall health Program

Title:

NTRK, RET, BRAF, and ALK Fusions in Thyroid Good-Needle Aspirates (FNAs). (poster presentation)

Abstract #:

6083

Very first Author:

Lori J. Wirth, M.D., Massachusetts General Clinic

Title:

Detection of actionable molecular alterations as a result of blended DNA/RNA molecular profiling of biopsies gathered in early stage lung most cancers at time of prognosis. (on line abstract)

Abstract #:

e20546

Initial Creator:

Joshua Babiarz, Ph.D., Veracyte

About Veracyte

Veracyte (Nasdaq: VCYT) is a international genomic diagnostics business that increases client care by offering answers to scientific issues, informing analysis and treatment conclusions throughout the individual journey in cancer and other disorders. The company’s expanding menu of genomic assessments leverage advances in genomic science and technological innovation, enabling patients to stay away from dangerous, high priced diagnostic procedures and quicken time to proper treatment. The company’s exams in lung cancer, prostate cancer, breast most cancers, thyroid cancer, bladder most cancers and idiopathic pulmonary fibrosis are obtainable to clients and its lymphoma subtyping and renal cancer checks are in enhancement. With Veracyte’s special world wide license to a finest-in-class diagnostics instrument system, the corporation is positioned to supply its assessments to patients throughout the world. Veracyte is based mostly in South San Francisco, California. For far more data, remember to stop by www.veracyte.com and stick to the firm on Twitter (@veracyte).

Cautionary Take note Relating to Forward-Seeking Statements

This push launch contains forward-looking statements, together with, but not minimal to, our statements linked to our designs, goals, anticipations (financial and in any other case) or intentions with regard to the Percepta Nasal Swab and our Decipher prostate and Veracyte thyroid assessments. Forward-seeking statements can be determined by text this sort of as: “foresee,” “intend,” “plan,” “anticipate,” “think,” “need to,” “suggest,” “may well,” “will” “prospective” and similar references to long run intervals. Real final results could vary materially from all those projected or instructed in any forward-hunting statements. Examples of ahead-wanting statements involve, amongst some others, statements concerning Veracyte’s belief that its Percepta Genomic Atlas Nasal Swab and our Envisia Decipher prostate and Veracyte thyroid exams supply clinical price that assists physicians diagnose and deal with lung cancer. Extra components that could influence these forward-wanting statements can be discovered below the caption “Chance Things” in our Annual Report on Sort 10-K filed with the SEC on February 22, 2021 and our subsequent quarterly reports on Sort 10-Q. A duplicate of these paperwork can be identified at the Buyers portion of our internet site at www.veracyte.com. The dangers and uncertainties may perhaps be amplified by the COVID-19 pandemic, which has caused substantial financial uncertainty. The extent to which the COVID-19 pandemic impacts Veracyte’s organizations, functions, and monetary results, like the duration and magnitude of these types of results, will rely on a lot of components, which are unpredictable, including, but not minimal to, the period and spread of the outbreak, its severity, the actions to include the virus or treat its impression, and how immediately and to what extent standard financial and operating situations can resume. These ahead-seeking statements converse only as of the day hereof and, except as required by law, Veracyte specially disclaims any obligation to update these ahead-hunting statements or causes why precise outcomes could differ, whether or not as a final result of new details, future events or or else.

Veracyte, Afirma, Percepta, Envisia, Prosigna, “Know by Design” and the Veracyte, Afirma, Percepta, Envisia and Prosigna logos are registered emblems of Veracyte in the U.S. and selected countries.

Look at supply model on businesswire.com: https://www.businesswire.com/news/household/20210429005432/en/

Contacts

Tracy Morris
Vice President of Company Communications
& Investor Relations
[email protected]
650-380-4413

Next Post

Some Californians Can not Get Vaccine Inspite of Surge in Supply | Wellbeing Information

By JANIE HAR, Linked Press SAN FRANCISCO (AP) — Hearing of extra vaccine and unfilled appointments frustrates Dr. Aaron Roland, a spouse and children medical doctor who has been lobbying for doses to inoculate his patients, many of whom are very low-money, immigrants or aged. The San Francisco Bay Location […]

Subscribe US Now